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The role of systemic hypertension in the progression of nondia- hemodynamics had become available. Elegant experimen-
betic renal disease. tal studies have suggested that systemic hypertension can
Background. A role for hypertension in the progression of be transmitted to glomeruli and that glomerular hyper-
renal disease has been convincingly shown in experimental
tension is harmful to the kidney [1]. Although the hyper-animals only. In human studies, the relation between hyperten-
trophic hyperplastic processes that follow any loss ofsion and progression is difficult to demonstrate due to several
nephrons and the increased protein ultrafiltration areconfounding factors: age, gender, race; the difficult choice of
blood pressure (BP) parameters that correlate with progres- also important factors [2, 3] there is a clear relation
sion; the abnormal circadian BP pattern; and the many non- between hypertension and progression of renal disease.
hemodynamic factors of progression. An important role for The application of the results of experimental studies
hypertension in progressive nondiabetic renal disease has been
to clinical practice has proved to be difficult for severalsuggested by observational studies and clinical trials originally
reasons. In experimental studies, the study population,intended to evaluate the effect of dietary protein restriction
the renal disease, and its duration were carefully definedon progression. In addition, several studies, summarized by a
recent meta-analysis, have shown that pharmacological agents and made uniform. In humans, chronic renal failure is
which lower both BP and proteinuria, mainly the angiotensin- a rather complex syndrome: its etiology is heteroge-
converting enzyme inhibitors (ACEI), significantly slow the neous, its clinical expression is greatly variable, and the
rate of progression in these diseases.
pathogenesis of progressive functional deterioration isMethods. In this article we review the effect of lowering BP
certainly multifactorial, resulting in a largely unpredict-on the progression of nondiabetic chronic renal disease, the
able rate of progression.patient characteristics that are associated with a greater or
lesser benefit of blood pressure reduction, and the choice of The relation between hypertension and progression
antihypertensive regimens associated with better outcomes in is difficult to demonstrate due to several confounding
patients with renal disease. factors. They include age, gender, and race; the difficult
Results. Lower levels of achieved BP are associated with a choice of BP parameters (systolic BP, diastolic BP, meanslower decline in renal function, both in patients with and
arterial pressure) that correlate better with progression;without proteinuria. ACEI are effective BP lowering agents
the abnormal circadian BP pattern which may be seen inand are associated with better preservation of renal function
as opposed to antihypertensive regimens without ACEI. This renal disease; the lack of a direct measure of glomerular
protective effect of ACEI is in addition to their BP and urine capillary pressure; and finally, the many non-hemody-
protein lowering effects. The protective effect of ACEI on namic factors of progression [4].
renal function is more pronounced in patients with proteinuria. We first discuss observational studies and clinical trialsConclusion. In patients with nondiabetic renal disease and
of dietary protein restriction which correlated blood pres-proteinuria, the risk of progression can be minimized by low-
sure levels to the decline in renal function. Thereafter weering both BP and proteinuria. ACEI have an additional bene-
ficial effect. discuss randomized trials comparing the effects of differ-
ent target blood pressures and different antihypertensive
agents on the progression of renal disease. We conclude
with a discussion of the effects of proteinuria and achievedA role for hypertension in the progression of renal dis-
blood pressure on the progression of renal disease.ease has been convincingly shown in experimental animals
only when suitable techniques to assess intraglomerular
OBSERVATIONAL STUDIES AND CLINICAL
TRIALS OF DIETARY PROTEIN RESTRICTIONKey words: blood pressure, angiotensin-converting enzyme inhibitors,
protein restriction. In a retrospective review of the records of 86 patients
with renal diseases of various etiology, Brazy et al [5]Ó 2000 by the International Society of Nephrology
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mm Hg, respectively). In both BP groups, enalapril or
diltiazem, with or without diuretics, were the agents of
choice for treatment of hypertension. The comparison
of randomized groups showed a significantly greater ben-
eficial effect of the low BP goal on the decline in renal
function in patients with higher baseline urine protein
excretion. In addition, combining patients in both ran-
domized groups showed that a lower achieved BP was
significantly correlated with a slower rate of decline in
glomerular filtration rate (GFR), especially in patients
with higher baseline urine protein excretion [9]. In pa-Fig. 1. Renal survival probability (Kaplan-Meier estimates) in 423 pa-
tients with baseline urine protein excretion . 1 g/day,tients with nondiabetic renal disease and chronic renal failure. “Renal
death” 5 serum creatinine values .10 mg/dL (see [6]). the rate of loss in renal function was minimal when the
achieved MAP was , 92 mm Hg. In patients with base-
line urine protein excretion , 1 g/day, renal function
decline was minimal when MAP was , 98 mm Hg.observed that the rate of decline in reciprocal serum
creatinine versus time was significantly lower in patients
with a mean diastolic BP of less than 90 mm Hg than it RANDOMIZED TRIALS COMPARING
was in those with higher diastolic BP values. PHARMACOLOGICAL AGENTS
Oldrizzi et al [6], in a study performed in 423 patients
Early randomized trials of ACEI
with renal diseases of various origin on long-term low
The results of early randomized trials were not uni-protein diet, found that the survival probability of renal
form. Some studies concluded that ACEI slowed pro-function at 10 years was 96% in patients with a mean BP
gression more than other antihypertensive agents. Otherlower than 100 mm Hg; it fell to 74% in patients with a
studies showed no significant difference between ACEImean BP between 100 and 110 mm Hg, and to only 48%
and other antihypertensive agents. Among the many pos-in those with a mean BP exceeding 110 mm Hg. The
sible explanations for the variation in results of thesedifference was statistically significant and was indepen-
trials is small sample size, leading to a wide confidencedent of the diagnosis of underlying renal disease (Fig. 1).
interval for the effect size in each trial. Overall, theseIn the Northern Italian Cooperative Study [7]—again
studies did not provide a clear picture of the benefits ofintended to evaluate the role of dietary protein restric-
ACEI in slowing the progression of renal disease.tion on progression of renal failure in 456 patients with
Zucchelli et al [10] compared the effect of captoprilrenal diseases of various origin: underlying nephropathy,
versus nifedipine in 121 patients with primary chronicbaseline serum creatinine (SCr) and proteinuria appeared
renal diseases and mild to moderate renal failure. Allto be more important than systemic hypertension in af-
patients were prescribed conventional antihypertensivefecting progression to end-stage renal disease (ESRD).
agents for one year. They were then randomized to re-Hypertensive patients, however, with a mean BP higher
ceive either captopril or nifedipine for two years duringthan 107 mm Hg had the worst cumulative renal survival.
which the further reduction in BP was similar in bothThese studies were not conducted to evaluate the spe-
groups. Although a fall in urine protein excretion wascific role of hypertension on progression. In addition,
more evident in ACEI-treated patients, the decline inwhen these studies were planned, the renoprotective ef-
GFR was similar between groups. Thus, the authors werefect of some antihypertensive agents, such as calcium
not able to evaluate the specific role of BP reduction inchannel blockers and angiotensin-converting enzyme in-
this study. However, the subgroup of patients in bothhibitors (ACEI), was not fully understood.
groups with a mean BP lower than 100 mm Hg had a
significantly slower rate of deterioration of renal function
THE MODIFICATION OF DIET AND RENAL than did those with higher mean BP values.
DISEASE STUDY Eight studies compared the effects of enalapril to con-
ventional antihypertensive agents without calcium chan-The Modification of Diet and Renal Disease (MDRD)
Study is the only large randomized trial directly compar- nel blockers ([11–15], and two unpublished studies
[Brenner and Toto, personal communications]. Alto-ing two levels of target BP in patients with predominantly
nondiabetic renal disease [8]. In this study, patients were gether, these studies included 760 patients. A beneficial
effect of enalapril was noted in three studies [11, 13, 14],randomized to different protein intakes and BP groups
in a “two-by-two factorial design.” The two target levels while no beneficial effect was observed in three pub-
lished [12, 13, 15] and two unpublished studies).of BP were mean arterial pressure (MAP) , 107 versus
, 92 mm Hg (equivalent to BP , 140/90 versus , 125/75 Himmelmann et al [16] compared the effects of cilaza-
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pril versus atenolol in 260 patients with a presumed diag- In both stratum 1 and stratum 2, the regression ana-
lyzes showed that only a part of the beneficial effect ofnosis of hypertensive nephrosclerosis and near-normal
renal function (mean GFR 82 mL/min/1.73 m2). Over a ramipril could be explained by its antihypertensive ef-
fect, but all of the beneficial effect could be explained2-year follow-up, the decline in renal function was
slightly but significantly slower in the ACEI group. by its antiproteinuric effect.
The ACE Inhibition and Progressive Renal DiseaseThe ACE Inhibition in Progressive Renal
Insufficiency (AIPRI) Study (AIPRD) Study Group
The AIPRD Study Group performed a meta-analysisIn the AIPRI Study [17], more than 600 patients with
renal diseases of various etiology and with mild to mod- of 11 of the randomized trials discussed above. Alto-
gether these trials included 1760 patients with nondia-erate renal insufficiency (creatinine clearance 60–30 mL/
min) received various antihypertensive agents to reduce betic renal disease, comparing antihypertensive regimens
containing ACEI to those not containing ACEI [20].BP during a 3-month period. Eventually, 583 patients were
randomized to either benazepril or placebo, with target There was a significantly lower risk of ESRD in the
ACEI group (relative risk 0.69, 95% confidence intervala diastolic BP lower than 90 mm Hg. Concomitant anti-
hypertensive treatment was balanced in the two groups. 0.53–0.91). The authors concluded that antihypertensive
regimens containing ACEI were more effective in slow-The comparison of randomized groups showed a bene-
ficial effect of benazepril on the primary outcome, a two- ing the progression to ESRD than regimens without
ACEI. However, the weighted decline in mean systolicfold increase (doubling) in baseline serum creatinine. In
addition, the benazepril group had a lower achieved BP and diastolic BP were 4.9 and 1.2 mm Hg lower, respec-
tively, in patients who received ACEI. Urine proteinand lower urine protein excretion during follow-up. The
target diastolic BP was achieved by 82% of patients in excretion was not reported consistently in these trials.
Since the meta-analysis was based on group data, ratherthe ACEI group and by 68% of those in the control
group. The mean values of diastolic BP throughout the than individual patient data, the authors could not deter-
study were below 85 mm Hg in the ACEI group and mine whether the benefit of ACEI is mediated by low-
below 90 mm Hg in the control group. This difference ering blood pressure or urine protein excretion.
might have contributed to the observed better renal sur- Since then, the AIPRD Study Group has reported
vival in this latter subgroup, although only part of the preliminary data from a pooled analysis of individual
risk reduction afforded by the ACEI could be statistically patient data from these 11 randomized controlled trials
explained by its greater antihypertensive effect. Simi- to determine whether the protective effect of ACEI was
larly, only part of the risk reduction afforded by the independent of changes in BP and proteinuria over time
ACEI could be explained by its greater antiproteinuric (abstract; Jafar et al, J Am Soc Nephrol 10:77A, 1999).
effect. Comparison of randomized groups confirmed the bene-
ficial effect of ACEI on reducing the risk of ESRD.
The Ramipril Efficacy in Nephropathy (REIN) Study Combining patients in both randomized groups, a greater
Ruggenenti and colleagues [18] compared the effect decline in BP and a greater decline in urine protein
of ramipril versus placebo on the decline in GFR and excretion were both associated with a lower risk of
on the combined endpoint, a twofold increase in serum ESRD. However, even after adjusting for the changes
creatinine or the onset of ESRD. The study was stratified in BP and proteinuria, the ACEI group had a lower risk
according to the level of proteinuria. Stratum 2 included of ESRD. The authors concluded that the protective
a total of 166 patients with nephrotic range proteinuria effect of ACEI is in addition to the benefit conferred by
(.3 g/day). The mean BP was similar in both groups. lowering BP and proteinuria.
The decline in urine protein excretion was significantly
greater in the ramipril versus the placebo group as was
EFFECT OF BASELINE URINE PROTEINmean decline in GFR. Significantly fewer patients in
ON THE CHOICE OFthe ramipril group reached the combined endpoint of
ANTIHYPERTENSIVE MEDICATIONSdoubling of baseline serum creatinine or end-stage renal
In the AIPRI Study [17], subgroup analysis was per-failure than in the control group.
formed to compare the beneficial effect of benazeprilStratum 1 of the REIN study [19] included 186 patients
according to baseline urine protein excretion. The riskwith proteinuria of 1–3 g/day randomized to ramipril
reduction (and 95% CI) for developing the combinedversus placebo. The decline in diastolic BP was greater
outcome of doubling of baseline serum creatinine or end-in the ramipril group as was the decline in proteinuria.
stage renal disease was 66% (34% to 82%) in patientsThe mean decline in GFR was not significantly different
with baseline proteinuria exceeding 3.0 g/day, as com-in the two groups. However, progression to ESRD was
significantly less common in the ramipril group. pared to 53% (214% to 81%) in those with baseline
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as well as in patients with nephrotic syndrome, but their
efficacy in patients with minimal or no proteinuria re-
mains questionable.
TARGET LEVEL OF BLOOD PRESSURE TO
ACHIEVE PROTECTION
Several controlled trials, as summarized in a recent
meta-analysis [21], have indicated that systolic BP is a
more important risk factor for both cardiovascular and
renal diseases than diastolic BP. The relationship be-
tween BP and risk of ESRD is stronger for systolic than
diastolic BP [21].
Fig. 2. Renal survival probability (Kaplan-Meier estimates) in 139 pa- Recommendations from the Sixth Report of the U.S.
tients with nondiabetic renal disease and proteinuria .1.0 ,3.0 g/day. Joint National Committee (JNC VI) for the Detection,
“Renal death” 5 doubling of baseline serum creatinine (see [17]).
Evaluation and Treatment of High Blood Pressure ad-
vise a target BP of , 140/90 mm Hg in hypertensive
patients without end-organ damage, and , 130/85 mm
Hg in patients with chronic renal insufficiency [22].proteinuria between 1.0 and 3.0 g/day, and 31% (267%
As discussed above, the MDRD Study showed a lowerto 71%) in those with baseline proteinuria of less than
achieved MAP was associated with a slower GFR de-1.0 g/day. Thus, the benefit of ACEI, although greater
cline, especially in patients with higher baseline urinein patients with greater proteinuria, was also observed
protein excretion. The authors concurred with the rec-in those with non-nephrotic range proteinuria (Fig. 2).
ommendations of the JNC VI for patients without pro-These results were subsequently confirmed in the
teinuria, but recommended a lower BP goal (MAP ,REIN trial [18, 19]. The risk ratio for the development
92 mm Hg, equivalent to BP , 125/75) in patients withof combined outcome (doubling of baseline serum creati-
proteinuria (defined arbitrarily as urine protein excre-nine or ESRD) for the placebo versus ramipril group
tion . 1 g/day).varied according to the level of proteinuria.
The AIPRD Study Group evaluated role of achievedIn stratum 2, the relative risk for placebo versus rami-
systolic BP (SBP) on progression, controlling for antihy-pril in patients with proteinuria of . 7.0 g/day, 4.5–7.0
pertensive agents (ACEI versus others) and baseline pro-g/day, and 3.0–4.5 g/day were 3.4, 2.1 and 1.7, respec-
tively. In stratum 1, subgroup analysis was performed teinuria (abstract; Jafar et al, J Am Soc Nephrol 10:77A,
according to the level of proteinuria in patients with 1999). Their preliminary results reported that the bene-
GFR of less than 45 mL/min. The relative risk of the ficial effect of lower achieved SBP during follow-up was
combined outcome for placebo versus ramipril were 2.8 greater in patients with higher baseline urine protein
and 1.2 in patients with proteinuria of greater than 1.5 excretion. However, even at lower urine protein excre-
g/day and less than 1.5 g/day, respectively. The authors tion (0.5 g/day) a lower SBP (120 mm Hg) appeared
concluded that the benefit of ramipril is greater at higher beneficial. There was no interaction between achieved
levels of proteinuria. SBP and antihypertensive agents, indicating that ACEI
The AIPRD Study Group also reported preliminary had greater beneficial effects than other antihypertensive
data showing greater benefit of ACEI in patients with agents, even at low SBP.
higher levels of urine protein excretion (abstract; Jafar A statistical evaluation on diastolic BP (DBP) levels
et al, J Am Soc Nephrol 10:77A, 1999). Although the has not been completed as yet. Again, the AIPRI Trial
magnitude of benefit of ACEI is comparatively lower in [17] suggested that the survival of residual renal function
patients with low levels of urine protein excretion, the may be significantly better preserved when DBP is kept
beneficial effect appears to persist even at levels of urine below 85 mm Hg than it is at values higher only by 4–5
protein excretion in the range of 0.5–1.0 g/day. Subgroup mm Hg.
analysis showed a significantly lower risk of ESRD in
the subgroup of patients with baseline urine protein ex-
SUMMARYcretion between 0.5 and 3.0 g/24 h (abstract; Jafar et al,
Overall, a lower SBP minimizes the risk of progressionJ Am Soc Nephrol 10:77A, 1999).
to ESRD, especially in patients with proteinuria. Antihy-Thus, the beneficial effect of ACEI on slowing the
pertensive regimens containing ACEI are better at pre-progression of renal disease is greater in patients with
serving renal function than regimens without ACEI. Thehigher baseline urine protein excretion. They appear to
be effective in patients with non-nephrotic proteinuria beneficial effect of ACEI is more pronounced in patients
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Stallone C, Sanna G, Gaggi R: Long-term comparison betweenwith proteinuria. This protective effect of ACEI is in
captopril and nifedipine in the progression of renal insufficiency.
addition to their BP and urine protein lowering effects. Kidney Int 42:452–458, 1992
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the progression of chronic renal failure. A randomized controlledslowing the rate of progression of non diabetic renal
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